Wassillios G Meissner

List of Publications by Year in Descending Order

179 papers	8,113 citations	46 h-index	86 g-index
203 ext. papers	9,995 ext. citations	6 avg, IF	5.6 L-index

#	Paper	IF	Citations
179	Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology.. *Brain*, **2022**,	11.2	1
178	Caregiver Burden in Late-Stage Parkinsonism and Its Associations. *Journal of Geriatric Psychiatry and Neurology*, **2022**, 35, 110-120	3.8	9
177	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. *Movement Disorders*, **2022**,	7	19
176	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. *Brain*, **2021**,	11.2	6
175	An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale. *Parkinsonism and Related Disorders*, **2021**, 94, 40-44	3.6	0
174	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [C]PBR28 and Machine Learning Analysis. *Movement Disorders*, **2021**,	7	3
173	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. *Lancet Neurology, The*, **2021**, 20, 182-192	24.1	29
172	Factors Associated with Health-Related Quality of Life in Late-Stage Parkinson's Disease. *Movement Disorders Clinical Practice*, **2021**, 8, 563-570	2.2	4
171	Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. *Movement Disorders*, **2021**, 36, 1499-1510	7	5
170	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. *Movement Disorders Clinical Practice*, **2021**, 8, 322-340	2.2	3
169	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. *Movement Disorders*, **2021**, 36, 1704-1711	7	3
168	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. *Parkinsonism and Related Disorders*, **2021**, 86, 124-132	3.6	5
167	Brain 5-HT1A Receptor Binding in Multiple System Atrophy: An [F]-MPPF PET Study. *Movement Disorders*, **2021**, 36, 246-251	7	4
166	A Phase 2 Randomized Trial of Asleep versus Awake Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease. *Stereotactic and Functional Neurosurgery*, **2021**, 99, 230-240	1.6	3
165	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. *Movement Disorders*, **2021**, 36, 449-459	7	2
164	Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home. *Journal of the American Medical Directors Association*, **2021**, 22, 440-445.e2	5.9	7
163	Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease. *Frontiers in Aging Neuroscience*, **2021**, 13, 632891	5.3	3

162	Safety and Tolerability of Active Immunotherapy Targeting Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. *Journal of Parkinsonls Disease*, **2021**, 11, 1079-1089	5.3	7
161	A Modified Progressive Supranuclear Palsy Rating Scale. *Movement Disorders*, **2021**, 36, 1203-1215	7	5
160	Overexpression of Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy. *Cells*, **2020**, 9,	7.9	4
159	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. *Brain*, **2020**, 143, 1780-1797	11.2	21
158	Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases. *European Journal of Neurology*, **2020**, 27, 1493-1500	6	5
157	Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations. *Parkinsonism and Related Disorders*, **2020**, 76, 56-62	3.6	12
156	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. *Journal of Parkinsonls Disease*, **2020**, 10, 1171-1184	5.3	3
155	Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. *Neurobiology of Disease*, **2020**, 139, 104813	7.5	13
154	The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism. *Movement Disorders Clinical Practice*, **2020**, 7, 531-542	2.2	7
153	Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. *Movement Disorders*, **2020**, 35, 1163-1172	7	4
152	Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease. *Neurology*, **2020**, 94, e2189-e2202	6.5	16
151	The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications. *Parkinsonism and Related Disorders*, **2020**, 75, 91-96	3.6	14
150	Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study. *Drugs and Aging*, **2020**, 37, 215-223	4.7	7
149	Addressing knowledge gaps in Parkinson's disease: a report on the Movement Disorder Society's Centre-to-Centre initiative to improve Parkinson's disease services in Lao People's Democratic Republic. *BMC Medical Education*, **2020**, 20, 239	3.3	2
148	Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. *Journal of Neural Transmission*, **2020**, 127, 1607-1617	4.3	1
147	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. *Movement Disorders Clinical Practice*, **2020**, 7, 750-762	2.2	13
146	Clinical Conditions "Suggestive of Progressive Supranuclear Palsy"-Diagnostic Performance. *Movement Disorders*, **2020**, 35, 2301-2313	7	15
145	A Phase 1 Randomized Trial of Specific Active Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. *Movement Disorders*, **2020**, 35, 1957-1965	7	20

144	Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease. *Movement Disorders*, **2020**, 35, 2101-2106	7	4
143	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. *Movement Disorders*, **2020**, 35, 171-176	7	23
142	The European Reference Network for Rare Neurological Diseases. *Frontiers in Neurology*, **2020**, 11, 616569	4.1	8
141	Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. *Neurology*, **2019**, 93, 630-639	6.5	38
140	Four-repeat tauopathies. *Progress in Neurobiology*, **2019**, 180, 101644	10.9	77
139	A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control. *NeuroImage: Clinical*, **2019**, 23, 101858	5.3	10
138	Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease. *Journal of Neural Transmission*, **2019**, 126, 789-793	4.3	1
137	Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. *Parkinsonism and Related Disorders*, **2019**, 64, 226-234	3.6	3
136	A critique of the second consensus criteria for multiple system atrophy. *Movement Disorders*, **2019**, 34, 975-984	7	44
135	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. *Movement Disorders*, **2019**, 34, 1228-1232	7	56
134	Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. *Parkinsonism and Related Disorders*, **2019**, 63, 199-203	3.6	11
133	Multiple System Atrophy: Recent Developments and Future Perspectives. *Movement Disorders*, **2019**, 34, 1629-1642	7	28
132	Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. *JCI Insight*, **2019**, 4,	9.9	30
131	Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort. *Journal of Clinical Psychiatry*, **2019**, 80,	4.6	14
130	Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. *Parkinsonism and Related Disorders*, **2019**, 60, 51-56	3.6	7
129	MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. *Movement Disorders*, **2018**, 33, 600-608	7	43
128	Stratégies thérapeutiques ciblant l'alpha-synucléine pour le traitement de la maladie de Parkinson et des autres synucléinopathies. *Pratique Neurologique - FMC*, **2018**, 9, 156-161	0	
127	Present and future of disease-modifying therapies in multiple system atrophy. *Autonomic Neuroscience: Basic and Clinical*, **2018**, 211, 31-38	2.4	5

126	Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy. *Neurobiology of Disease*, **2018**, 118, 155-160	7.5	3
125	Factors associated with spousal burden in Parkinson's disease. *Revue Neurologique*, **2018**, 174, 711-715	3	16
124	Lysosomal storage disorder gene variants in multiple system atrophy. *Brain*, **2018**, 141, e53	11.2	7
123	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. *Parkinsonism and Related Disorders*, **2018**, 56, 33-40	3.6	14
122	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. *Neurology*, **2018**, 90, 74-82	6.5	10
121	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. *BMC Neurology*, **2018**, 18, 185	3.1	19
120	LRP10 in synucleinopathies. *Lancet Neurology, The*, **2018**, 17, 1033-1034	24.1	9
119	Impact of sleep apnea syndrome on survival in patients with multiple system atrophy. *Parkinsonism and Related Disorders*, **2017**, 35, 92-95	3.6	5
118	Epidemiology, environmental risk factors and genetics of Parkinson's disease. *Presse Medicale*, **2017** , 46, 175-181	2.2	87
117	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. *Movement Disorders*, **2017**, 32, 995-1005	7	88
116	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Movement Disorders*, **2017**, 32, 853-864	7	840
115	Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. *Movement Disorders*, **2017**, 32, 1230-1239	7	31
114	Multiple System Atrophy - State of the Art. *Current Neurology and Neuroscience Reports*, **2017**, 17, 41	6.6	21
113	Insulin resistance and exendin-4 treatment for multiple system atrophy. *Brain*, **2017**, 140, 1420-1436	11.2	50
112	L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. *European Journal of Neurology*, **2017**, 24, 1532-1538	6	33
111	Analysis of the prion protein gene in multiple system atrophy. *Neurobiology of Aging*, **2017**, 49, 216.e15-216.e18	5.1	4
110	Exosomes, an Unmasked Culprit in Neurodegenerative Diseases. *Frontiers in Neuroscience*, **2017**, 11, 26	5.1	86
109	Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 9593-8	11.5	67

108	A genome-wide association study in multiple system atrophy. *Neurology*, **2016**, 87, 1591-1598	6.5	104
107	Targeting □synuclein: Therapeutic options. *Movement Disorders*, **2016**, 31, 882-8	7	33
106	New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 554-61	5.5	30
105	Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature. *Parkinsonism and Related Disorders*, **2016**, 24, 69-75	3.6	29
104	Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. *Movement Disorders*, **2016**, 31, 325-34	7	60
103	Delayed-onset Friedreich's ataxia revisited. *Movement Disorders*, **2016**, 31, 62-9	7	40
102	Presumed tuberculous retrobulbar optic neuritis: a diagnosis challenge. *Journal of Neurology*, **2015**, 262, 481-4	5.5	4
101	Current Concepts in the Treatment of Multiple System Atrophy. *Movement Disorders Clinical Practice*, **2015**, 2, 6-16	2.2	15
100	L□trophie multisyst□hatis□. *Pratique Neurologique - FMC*, **2015**, 6, 115-123	0	
99	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. *Progress in Neurobiology*, **2015**, 132, 96-168	10.9	282
98	Falls in ambulatory non-demented patients with Parkinson's disease. *Journal of Neural Transmission* , **2015**, 122, 1447-55	4.3	41
97	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. *Neurobiology of Disease*, **2015**, 80, 29-41	7.5	48
96	Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. *Parkinsonism and Related Disorders*, **2015**, 21, 1273-7	3.6	23
95	Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice. *Journal of Neurology*, **2015**, 262, 435-42	5.5	12
94	Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy. *Movement Disorders*, **2015**, 30, 1802-12	7	7
93	Targeting □synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. *Lancet Neurology, The*, **2015**, 14, 855-866	24.1	286
92	Facial emotion recognition is inversely correlated with tremor severity in essential tremor. *Journal of Neural Transmission*, **2014**, 121, 347-51	4.3	6
91	A cross-sectional study on drug use in multiple system atrophy. *CNS Drugs*, **2014**, 28, 483-90	6.7	8

90	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. *Movement Disorders*, **2014**, 29, 857-67	7	148
89	Movement disorders in 2013: diagnosing and treating PD-the earlier the better?. *Nature Reviews Neurology*, **2014**, 10, 65-6	15	5
88	Restless legs syndrome in multiple system atrophy. *Journal of Neural Transmission*, **2014**, 121, 1523-7	4.3	15
87	Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. *Neurobiology of Disease*, **2014**, 67, 133-9	7.5	25
86	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. *Progress in Neurobiology*, **2014**, 118, 1-18	10.9	143
85	L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. *Scientific Reports*, **2014**, 4, 3730	4.9	53
84	Intra-axonal protein aggregation in the peripheral nervous system. *Journal of the Peripheral Nervous System*, **2014**, 19, 44-9	4.7	15
83	Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. *Synapse*, **2014**, 68, 98-106	2.4	29
82	Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. *Movement Disorders*, **2014**, 29, 388-95	7	25
81	Coordinated reset neuromodulation for Parkinson's disease: proof-of-concept study. *Movement Disorders*, **2014**, 29, 1679-84	7	143
80	Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. *Neurology*, **2014**, 82, 300-7	6.5	101
79	Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. *JAMA Neurology*, **2014**, 71, 884-90	17.2	159
78	Demyelination in a patient receiving ustekinumab for refractory Crohn's disease. *Journal of Crohnls and Colitis*, **2014**, 8, 1138-9	1.5	21
77	Accuracy of portable polygraphy for the diagnosis of sleep apnea in multiple system atrophy. *Sleep Medicine*, **2014**, 15, 476-9	4.6	2
76	[(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: A specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6). *NeuroImage: Clinical*, **2013**, 3, 212-7	5.3	15
75	The natural history of multiple system atrophy: a prospective European cohort study. *Lancet Neurology, The*, **2013**, 12, 264-74	24.1	322
74	Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. *Parkinsonism and Related Disorders*, **2013**, 19, 416-21	3.6	21
73	Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL). *Revue Neurologique*, **2013**, 169, 53-8	3	3

72	Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease: FRANCE. *Neurology: Clinical Practice*, **2013**, 3, 480-481	1.7	1
71	Improvement of in Vivo Quantification of [123I]-Iodobenzovesamicol in Single-Photon Emission Computed Tomography/Computed Tomography Using Anatomic Image to Brain Atlas Nonrigid Registration. *Molecular Imaging*, **2013**, 12, 7290.2012.00043	3.7	4
70	Isolated generalized dystonia in biallelic missense mutations of the ATM gene. *Movement Disorders*, **2013**, 28, 1897-9	7	17
69	Improvement of in vivo quantification of [123I]-Iodobenzovesamicol in single-photon emission computed tomography/computed tomography using anatomic image to brain atlas nonrigid registration. *Molecular Imaging*, **2013**, 12, 288-99	3.7	4
68	Coordinated reset has sustained aftereffects in Parkinsonian monkeys. *Annals of Neurology*, **2012**, 72, 816-20	9.4	194
67	Assessment of quality of life with the multiple system atrophy health-related quality of life scale. *Movement Disorders*, **2012**, 27, 1574-7	7	6
66	Methods for treating neurological conditions (WO2011159945). *Expert Opinion on Therapeutic Patents*, **2012**, 22, 847-52	6.8	
65	Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. *Parkinsonism and Related Disorders*, **2012**, 18, 612-5	3.6	16
64	FXTAS: new insights and the need for revised diagnostic criteria. *Neurology*, **2012**, 79, 1898-907	6.5	129
63	A long-term follow-up of weight changes in subthalamic nucleus stimulated Parkinson's disease patients. *Revue Neurologique*, **2012**, 168, 173-6	3	17
62	When does Parkinson's disease begin? From prodromal disease to motor signs. *Revue Neurologique*, **2012**, 168, 809-14	3	33
61	Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol. *Radiology*, **2012**, 265, 537-43	20.5	22
60	Ambiguous mechanisms of dysphagia in multiple system atrophy. *Brain*, **2012**, 135, e205; author reply e206	11.2	7
59	Subthalamic deep brain stimulation increases pallidal firing rate and regularity. *Experimental Neurology*, **2011**, 229, 517-21	5.7	40
58	Priorities in Parkinson's disease research. *Nature Reviews Drug Discovery*, **2011**, 10, 377-93	64.1	317
57	Acquired hepatocerebral degeneration. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2011**, 100, 193-7	3	19
56	Development of an implantable microstimulation system for chronic DBS in rodents. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2011**, 2011, 660-2	0.9	5
55	The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2011**, 2011, 663-6	0.9	

54	l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. *International Review of Neurobiology*, **2011**, 98, 31-54	4.4	39
53	Multiple system atrophy: current and future approaches to management. *Therapeutic Advances in Neurological Disorders*, **2010**, 3, 249-63	6.6	45
52	Normal cerebrovascular reactivity in Stroke-like Migraine Attacks after Radiation Therapy syndrome. *Clinical Nuclear Medicine*, **2010**, 35, 583-5	1.7	40
51	Deep brain stimulation changes basal ganglia output nuclei firing pattern in the dystonic hamster. *Neurobiology of Disease*, **2010**, 38, 288-98	7.5	18
50	Dyspnea as first sign of autonomic failure in postmortem confirmed multiple system atrophy. *Movement Disorders*, **2010**, 25, 1997-8	7	10
49	High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster. *Neurobiology of Disease*, **2009**, 35, 399-405	7.5	7
48	Dopamine transporter binding is reduced following disulfiram-induced striatal damage. *Movement Disorders*, **2009**, 24, 941-3	7	1
47	Opsoclonus myoclonus syndrome in the context of Salmonellosis. *Movement Disorders*, **2009**, 24, 2306-8	7	10
46	Axonal sensory motor neuropathy in copper-deficient Wilson's disease. *Muscle and Nerve*, **2009**, 40, 294-6	3.4	26
45	Use of the Triage Stroke Panel in a neurologic emergency service. *American Journal of Emergency Medicine*, **2009**, 27, 558-62	2.9	25
44	Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. *Neuroscience*, **2008**, 153, 1213-24	3.9	58
43	Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. *Experimental Neurology*, **2008**, 210, 257-60	5.7	48
42	Hearing and seeing: Unusual early signs of Wernicke encephalopathy. *Neurology*, **2008**, 71, 694	6.5	15
41	Subthalamic stimulation increases striatal tyrosine hydroxylase phosphorylation. *NeuroReport*, **2008**, 19, 179-82	1.7	6
40	High frequency stimulation of the subthalamic nucleus modulates neurotransmission in limbic brain regions of the rat. *Experimental Brain Research*, **2008**, 185, 497-507	2.3	50
39	Continuous high-frequency stimulation in freely moving rats: development of an implantable microstimulation system. *Journal of Neuroscience Methods*, **2008**, 167, 278-91	3	38
38	Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease. *European Journal of Neuroscience*, **2007**, 25, 1492-500	3.5	25
37	Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism. *European Journal of Neuroscience*, **2007**, 26, 1701-13	3.5	122

36	MRI versus CT in acute stroke. *Lancet, The*, **2007**, 369, 1342	40	1
35	Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. *Neurobiology of Disease*, **2006**, 22, 586-98	7.5	120
34	Fatal embolic myocardial infarction after systemic thrombolysis for stroke. *Cerebrovascular Diseases* , **2006**, 22, 213-4	3.2	22
33	Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia. *Journal of Neuroscience*, **2006**, 26, 3567-83	6.6	245
32	Reply to: Deep brain stimulation in Parkinson's disease can mimic the 300 Hz subthalamic rhythm Subthalamic high-frequency stimulation drives subthalamic oscillatory activity at stimulation frequency while firing rate is reduced. *Brain*, **2006**, 129, e60-e60	11.2	2
31	Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease. *Synapse*, **2006**, 60, 69-80	2.4	10
30	Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. *European Journal of Neuroscience*, **2006**, 24, 1201-8	3.5	44
29	Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. *Brain*, **2005**, 128, 2372-82	11.2	280
28	Coherent spike-wave oscillations in the cortex and subthalamic nucleus of the freely moving rat. *Neuroscience*, **2005**, 132, 659-64	3.9	33
27	Dopamine depletion increases the power and coherence of beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat. *European Journal of Neuroscience*, **2005**, 21, 1413-22	3.5	277
26	Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. *Journal of Neurology*, **2005**, 252, 218-23	5.5	54
25	High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism. *FASEB Journal*, **2004**, 18, 528-30	0.9	54
24	Deep brain stimulation for Parkinson's disease: potential risk of tissue damage associated with external stimulation. *Annals of Neurology*, **2004**, 55, 449-50	9.4	12
23	The effects of electrode material, charge density and stimulation duration on the safety of high-frequency stimulation of the subthalamic nucleus in rats. *Journal of Neuroscience Methods*, **2004**, 138, 207-16	3	103
22	Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. *Trends in Pharmacological Sciences*, **2004**, 25, 249-53	13.2	70
21	Subthalamic high frequency stimulation induced rotations are differentially mediated by D1 and D2 receptors. *Neuropharmacology*, **2004**, 46, 974-83	5.5	18
20	Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortex. *Neurochemistry International*, **2004**, 45, 995-1004	4.4	4
19	Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. *Experimental Neurology*, **2004**, 185, 272-80	5.7	67

18	High frequency stimulation of the entopeduncular nucleus has no effect on striatal dopaminergic transmission. *Neurochemistry International*, **2004**, 44, 281-6	4.4	22
17	High-frequency stimulation of the entopeduncular nucleus improves dystonia in dtsz hamsters. *NeuroReport*, **2004**, 15, 1391-3	1.7	17
16	The deafferented nonhuman primate is not a reliable model of intractable pain. *Neurological Research*, **2003**, 25, 127-9	2.7	5
15	Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. *Molecular Neurobiology*, **2003**, 28, 209-18	6.2	61
14	Deep brain stimulation in dystonia. *Journal of Neurology*, **2003**, 250 Suppl 1, I47-52	5.5	59
13	The effects of frequency in pallidal deep brain stimulation for primary dystonia. *Journal of Neurology*, **2003**, 250, 1201-5	5.5	68
12	High-frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats. *Journal of Neurochemistry*, **2003**, 85, 601-9	6	112
11	Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. *Neurobiology of Disease*, **2003**, 13, 46-54	7.5	27
10	Oscillatory local field potentials recorded from the subthalamic nucleus of the alert rat. *Experimental Neurology*, **2002**, 177, 581-5	5.7	74
9	Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. *Neuroscience Letters*, **2002**, 328, 105-8	3.3	99
8	Influence of Deep Brain Stimulation on Striatal Dopamine Release and Metabolism in the 6-Ohda-Model of Parkinson□ Disease. *Advances in Behavioral Biology*, **2002**, 77-86		
7	Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. *Movement Disorders*, **2001**, 16, 769-71	7	107
6	Pallidal and thalamic neurostimulation in severe tardive dystonia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 70, 557-9	5.5	96
5	Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. *Neuroscience Letters*, **2001**, 303, 165-8	3.3	74
4	High frequency stimulation of the subthalamic nucleus influences striatal dopaminergic metabolism in the naive rat. *NeuroReport*, **2000**, 11, 441-4	1.7	61
3	The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat. *Neuroscience Letters*, **2000**, 296, 149-52	3.3	15
2	Reversible leucopenia related to olanzapine. *Movement Disorders*, **1999**, 14, 872-3	7	22
1	AETIONOMY, a Cross-Sectional Study Aimed at validating a new taxonomy of Neurodegenerative Diseases: Study design and subject characteristics		2